Sugi Predict

Sugi Predict / Targets / SLK

SLK

STE20-like serine/threonine-protein kinase · Q9H2G2 · SLK on Sugi Atlas →

58,294 patent compounds predicted against SLK, 43,207 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL211026 SCHEMBL211026 0.46 8/20
SCHEMBL232042 SCHEMBL232042 1.00 5/20
SCHEMBL234334 SCHEMBL234334 1.00 5/20
SCHEMBL261439 SCHEMBL261439 0.47 5/20
SCHEMBL187280 SCHEMBL187280 0.42 5/20
SCHEMBL54436 SCHEMBL54436 0.36 5/20
SCHEMBL147422 SCHEMBL147422 0.66 4/20
SCHEMBL144979 SCHEMBL144979 0.56 4/20
SCHEMBL299518 SCHEMBL299518 0.76 3/20
SCHEMBL146734 SCHEMBL146734 0.67 3/20
SCHEMBL144651 SCHEMBL144651 0.67 3/20
SCHEMBL146677 SCHEMBL146677 0.67 3/20
Sb-203580 Sb-203580 (SCHEMBL95208) 0.67 3/20
Sb-203580 Sb-203580 (SCHEMBL146399) 0.67 3/20
Pd-169316 Pd-169316 (SCHEMBL154958) 0.67 3/20
Sb-203580 Sb-203580 (SCHEMBL220990) 0.67 3/20
SCHEMBL142020 SCHEMBL142020 0.65 3/20
SCHEMBL148704 SCHEMBL148704 0.62 3/20
SCHEMBL147730 SCHEMBL147730 0.61 3/20
SCHEMBL148478 SCHEMBL148478 0.61 3/20

Clinical trials — most relevant to SLK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI PHASE1/PHASE2UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients PHASE2COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Salt Sensitivity Hypertension and Lens Opacities nanCOMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLK binder may also engage these)

ProteinNameSimilarity
O55092 — 1.000 O55092 →
O54988 — 1.000 O54988 →
O08815 — 0.999 O08815 →
A6QP06 — 0.993 A6QP06 →
EPB41 Protein 4.1 0.992 landscape →
P48193 — 0.992 P48193 →
F1NBT0 — 0.991 F1NBT0 →
Q05D44 — 0.990 Q05D44 →
EPB41L2 Band 4.1-like protein 2 0.990 landscape →
Q7SY52 — 0.989 Q7SY52 →
Q60MF5 — 0.989 Q60MF5 →
Q9HCH5 — 0.989 Q9HCH5 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.988 landscape →
Q8N573 — 0.988 Q8N573 →
A8KBE0 — 0.988 A8KBE0 →
Q6Q7P4 — 0.988 Q6Q7P4 →
Q28Z18 — 0.988 Q28Z18 →
Q8RWK8 — 0.988 Q8RWK8 →
EIF5B Eukaryotic translation initiation factor 5B 0.988 landscape →
Q99PI5 — 0.988 Q99PI5 →
B4GT53 — 0.988 B4GT53 →
O13870 — 0.988 O13870 →
Q9NQW6 — 0.988 Q9NQW6 →
Q9UPS8 — 0.988 Q9UPS8 →
Q8WML3 — 0.988 Q8WML3 →
O75167 — 0.988 O75167 →
Q6DFV7 — 0.988 Q6DFV7 →
Q5S003 — 0.987 Q5S003 →
Q8NDI1 — 0.987 Q8NDI1 →
P38806 — 0.987 P38806 →